# UCB Pharma clinical trials: 242 on ClinicalTrials.gov (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 242 trials with UCB Pharma as lead sponsor, 0 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by UCB Pharma: 242 rows for $12.10, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/ucb-pharma

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 242
- Recruiting or not yet: 0
- Read on: November 19, 2026

## Trials

The 25 newest of 242, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 11, 2015 | NCT02602860 | A Brain Imaging Study With Positron Emission Tomography and the Radiotracer \[11C\]UCB-J to Estimate How Fast Brivaracetam and Levetiracetam... | UCB Pharma | Phase 1 | Completed | Healthy Volunteers | 13 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02602860) |
| December 1, 2014 | NCT02303509 | Study to Assess Safety, Tolerability, Pharmacokinetic & Pharmacodynamic Effect of UCB5857 in Healthy & Psoriatic Subject | UCB Pharma | Phase 1 | Completed | Psoriasis | 57 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02303509) |
| October 25, 2013 | NCT01969851 | A Study to Investigate the Safety and Efficacy of Lacosamide Added to the Patients Current Therapy in Patients Aged 1 Month to Less Than 18... | UCB Pharma | Phase 2 | Completed | Epilepsy | 55 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01969851) |
| October 17, 2013 | NCT01964573 | Trial to Evaluate the Pharmacokinetics, Safety, and Tolerability of Rotigotine in Healthy Korean Subjects | UCB Pharma | Phase 1 | Completed | Parkinson's Disease | 48 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01964573) |
| August 13, 2013 | NCT01921205 | Study to Investigate Lacosamide as Add-on Therapy in Subjects ≥4 Years to \<17 Years of Age With Partial Onset Seizures | UCB Pharma | Phase 3 | Completed | Epilepsy | 404 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01921205) |
| January 9, 2013 | NCT01764594 | Safety Study of CDP7657 in Patients With Systemic Lupus Erythematosus | UCB Pharma | Phase 1 | Completed | Immune System Diseases, Autoimmune Diseases, Lupus Erythematosus, Systemic, Skin and Connective Tissue Diseases... | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01764594) |
| August 29, 2012 | NCT01675024 | Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Rotigotine Transdermal Patch in Healthy Chinese Subjects | UCB Pharma | Phase 1 | Completed | Healthy | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01675024) |
| July 20, 2012 | NCT01646268 | Rotigotine Versus Placebo As Double Blind Study To Evaluate The Efficacy In Early Stage Idiopathic Parkinson's Disease Patients | UCB Pharma | Phase 3 | Completed | IDIOPATHIC PARKINSON'S DISEASE | 249 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01646268) |
| July 20, 2012 | NCT01646255 | Rotigotine Versus Placebo, A Study To Evaluate The Efficacy In Advanced Stage Idiopathic Parkinson's Disease Patients | UCB Pharma | Phase 3 | Completed | Idiopathic Parkinson's Disease | 346 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01646255) |
| June 13, 2012 | NCT01618903 | An Open-label, Bioequivalence Study to Evaluate LEV Administered as a 45-min Intravenous Infusion and Same Dosage LEV Oral Tablet in Chinese | UCB Pharma | Phase 1 | Completed | Human Volunteers | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01618903) |
| June 13, 2012 | NCT01618877 | A Randomized, Double-blind, Pharmacokinetics Study to Assess Safety, Tolerability of Levetiracetam 45 Minutes Intravenous Infusion During 4... | UCB Pharma | Phase 1 | Completed | Human Volunteers | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01618877) |
| April 13, 2012 | NCT01577264 | Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis (RA) and Crohn's Disease (CD) | UCB Pharma | Observational | Terminated | Rheumatoid Arthritis, Crohn's Disease | 199 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01577264) |
| April 3, 2012 | NCT01569464 | Rotigotine Effect on All-day Functioning and Quality of Life in Subjects With Moderate to Severe Restless Legs Syndrome (RLS) | UCB Pharma | Phase 3 | Completed | Restless Legs Syndrome | 150 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01569464) |
| March 28, 2012 | NCT01565018 | Bioequivalence Study of Rotigotine Transdermal Patch With Two Different Formulations in Healthy Japanese Subjects | UCB Pharma | Phase 1 | Completed | Healthy Volunteers | 55 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01565018) |
| February 20, 2012 | NCT01536015 | Effect of Rotigotine on Motor Symptoms in Patients With Advanced Parkinson's Disease (PD) With Motor Fluctuations and Symptoms of... | UCB Pharma | Phase 3 | Terminated | Advanced Parkinson's Disease | 25 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01536015) |
| February 16, 2012 | NCT01534403 | Open Label Extension Study of Epratuzumab in Japanese Systemic Lupus Erythematosus (SLE) Subjects | UCB Pharma | Phase 2 | Completed | Systemic Lupus Erythematosus | 17 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01534403) |
| February 9, 2012 | NCT01530386 | A Multicenter, Open-label Study to Determine the Effects of Lacosamide on Sleep in Healthy Subjects | UCB Pharma | Phase 1 | Completed | Healthy Subjects | 25 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01530386) |
| February 9, 2012 | NCT01530022 | Crossover Study of Neuropsychological Effects of Lacosamide and Carbamazepine Immediate Release in Healthy Subjects | UCB Pharma | Phase 1 | Completed | Healthy | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01530022) |
| February 3, 2012 | NCT01526083 | Effect of Lacosamide 200 mg Twice a Day (Bid) on Single Dose Warfarin 25 mg in Healthy Males | UCB Pharma | Phase 1 | Completed | Healthy Volunteers | 16 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01526083) |
| January 31, 2012 | NCT01521923 | A Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Certolizumab Pegol in Combination... | UCB Pharma | Phase 3 | Completed | Rheumatoid Arthritis | 359 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01521923) |
| January 5, 2012 | NCT01504529 | Non-interventional, Retrospective, Multi-center Study to Evaluate Non-motor Symptoms in Advanced Parkinson Disease (PD) Patients Already... | UCB Pharma | Observational | Completed | Parkinson's Disease | 391 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01504529) |
| December 13, 2011 | NCT01491113 | Pharmacokinetic (PK) Study in Japanese Non-epileptic Renal Impaired Patients | UCB Pharma | Phase 4 | Completed | Healthy Subjects, Renal Impairments | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01491113) |
| December 5, 2011 | NCT01484977 | eValuation of the Efficacy and toleRability of Vimpat When Added to lEvetiracetam | UCB Pharma | Phase 3 | Completed | Epilepsy | 120 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01484977) |
| October 12, 2011 | NCT01450111 | To Evaluate the Pharmacokinetics and Safety/Tolerability of Lacosamide in 3 Dosages in Healthy Male Korean Subjects | UCB Pharma | Phase 1 | Completed | Epilepsy | 51 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01450111) |
| October 7, 2011 | NCT01449071 | Study Evaluating the Pharmacokinetics and Safety of Epratuzumab in Japanese Systemic Lupus Erythematosus (SLE) | UCB Pharma | Phase 1/2 | Completed | Systemic Lupus Erythematosus | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01449071) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 29 |
| Phase 1/2 | 3 |
| Phase 2 | 49 |
| Phase 2/3 | 4 |
| Phase 3 | 107 |
| Phase 4 | 25 |
| Not applicable | 4 |
| Observational | 21 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 220 |
| Terminated | 16 |
| Withdrawn | 6 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Epilepsy | 56 |
| Parkinson Disease | 25 |
| Arthritis, Rheumatoid | 22 |
| Epilepsies, Partial | 17 |
| Crohn Disease | 15 |
| Lupus Erythematosus, Systemic | 14 |
| Seizures | 13 |
| Restless Legs Syndrome | 10 |
| Rhinitis, Allergic, Seasonal | 9 |
| Diabetic Neuropathies | 9 |
| Rhinitis | 5 |
| Arthritis | 4 |
| Hypersensitivity | 4 |
| Neuralgia, Postherpetic | 4 |
| Joint Diseases | 3 |
| Rhinitis, Allergic, Perennial | 3 |
| Epilepsy, Generalized | 3 |
| Rhinitis, Allergic | 3 |
| Chronic Urticaria | 3 |
| Epilepsy, Idiopathic Generalized | 2 |
| Anemia, Dyserythropoietic, Congenital | 2 |
| Anxiety Disorders | 2 |
| Psoriasis | 2 |
| Immune System Diseases | 2 |
| Autoimmune Diseases | 2 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Urology practices in the United States](https://specstream.ai/data/businesses/urology-practices/united-states)
- [Osteopathic practices in the United States](https://specstream.ai/data/businesses/osteopathic-practices/united-states)
- [Flooring contractors in the United States](https://specstream.ai/data/businesses/flooring-contractors/united-states)
- [Bankruptcy law firms in the United States](https://specstream.ai/data/businesses/bankruptcy-law-firms/united-states)
- [Sleep medicine clinics in the United States](https://specstream.ai/data/businesses/sleep-medicine-clinics/united-states)
- [Legal services firms in the United States](https://specstream.ai/data/businesses/legal-services-firms/united-states)
